By incorporating non-imaging data, the algorithm can effectively pinpoint which patients will need ICU intervention.
As the need for faster, accurate COVID-19 diagnostic tools continues to grow, another group of researchers has announced a tool that can help clinicians treat patients based on their specific needs and history.
Specifically, a team from Rensselaer Polytechnic Institute, with support from a National Institutes of Health grant, has developed a new algorithm that combines CT images of the patient’s lungs with non-imaging data, such as demographics, vital signs, and laboratory test results, to help providers pinpoint which COVID-19-positive patients will need intervention in the intensive care unit.
The team published the details of their algorithm recently in Medical Image Analysis.
To determine the algorithm’s efficacy, the team, led by Pingkun Yan, Ph.D., associate professor of biomedical engineering, tested the tool on datasets collected from 295 patients from three hospitals, one each in the United States, Iran, and Italy, comparing the algorithm’s treatment predictions to the treatment each patient actually needed and received.
Related Content: AI Algorithm Faster, More Accurate in Detecting COVID-19 on Chest X-rays
Based on their analysis, they determined that adding non-imaging features to the algorithm significantly improves prediction performance, enabling the algorithm to reach an AUC up to 0.884 and sensitivity as high as 96.1 percent. Consequently, Yan said, it can be a valuable clinical decision support tool for the management of COVID-19-positive patients.
“As a practitioner of AI, I do believe in its power,” he said. “It really enables us to analyze a large quantity of data and also extract the features that may not be that obvious to the human eye.”
In collaboration with researchers from Massachusetts General Hospital, Yan’s team is working to integrate this algorithm with another he previously developed that can use CT scans to assess cardiovascular disease risk. Underlying conditions, such as heart disease play a considerable role in COVID-19 mortality, he said, so being able to quantify a patient’s heart condition can help determine how the team can factor it into the AI prediction.
Ultimately, Yan said, the goal is to translate the algorithm into a method that doctors at Massachusetts General can use in clinical assessments – both with COVID-19 and beyond.
“We actually are seeing that the impact could go well beyond COVID diseases. For example, patients with other lung diseases,” he said. “Assessing their heart disease condition, together with their lung condition, could better predict their mortality risk so that we can help them to manage their condition.”
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.